Detail of "145158-71-0"

Reference

Effects of a 5-HT4 receptor agonist on esophageal function and gastro-esophageal reflux: studies using combined impedance-manometry and combined impedance-pH

All Rights Reserved. Effects of a 5-HT4 receptor agonist on esophageal function and gastro-esophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Tutuian, R.; Mainie, I.; Allan, R.; Hargreaves, K.; Agrawal, A.; Freeman, J.; Gale, J.; Castell, D. O. (Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC, USA). Alimentary Pharmacology and Therapeutics, 24(1), 155-162 (English) 2006 Blackwell Publishing Ltd.Some commonly used reagents like 145158-71-0 is used in this experiment. CODEN: APTHEN. ISSN: 0269-2813. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) 5-HT4 receptor agonists are used as promotility agents of the stomach, small and large intestine. There is limited information on the influence of 5-HT4 receptor agonists on esophageal function and gastro-esophageal reflux. The aim of this study was to evaluate the effects of tegaserod, a 5-HT4 agonist on esophageal function using impedance-manometry and postprandial reflux using impedance-pH monitoring. Twenty healthy volunteers were enrolled in a double-blind randomized three-period crossover placebo-controlled study. Impedance-manometry and impedance-pH monitoring after a refluxogenic meal were performed at baseline and after 2 days of dosing with tegaserod 6 mg b.d. or placebo. Multichannel intraluminal impedance-EM recorded pressure and bolus transit data during standardized swallows. Multichannel intraluminal impedance-pH monitoring recorded the no. of 2-h postprandial acid and non-acid reflux episodes. We found no significant difference in distal esophageal amplitude when subjects received placebo (median 94.5; range: 53-243 mmHg) or tegaserod (93.6; 43-216 mmHg). Bolus transit time was similar during dosing with placebo (7.1; 5.3-9.4 s) and tegaserod (7.2; 5.9-11.1 s). We obsd. similar nos. of acid and non-acid reflux episodes during dosing with placebo (5; 0-15 and 3; 0-18, resp.) and tegaserod (2; 0-11 and 4; 0-19, resp.). Tegaserod, a 5-HT4 receptor agonist does not change esophageal motility and gastro-esophageal reflux parameters in healthy volunteers. .

Functional dyspepsia: drugs for new (and old) therapeutic targets

Functional dyspepsia: drugs for new (and old) therapeutic targets. Cremonini, Filippo; Delgado-Aros, Silvia; Talley, Nicholas J. (Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA). Best Practice & Research, Clinical Gastroenterology, 18(4), 717-733 (English) 2004 Elsevier B.V. CODEN: BPRCB6. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. The therapeutic management of functional dyspepsia remains a major challenge for the gastroenterologist. Current therapies available are based on putative underlying pathophysiol. mechanisms, including gastric acid sensitivity, slow gastric emptying and Helicobacter pylori infection, but only a small proportion of patients achieve symptomatic benefit from these therapeutic approaches. Relatively novel mechanistic concepts under testing include impaired gastric accommodation, visceral hypersensitivity, and central nervous system dysfunction. Serotonergic modulators (e. 145158-71-0 and 174636-32-9 which are cas registry numbers are also used here.g. the 5-HT4 agonist tegaserod, the 5-HT3 antagonist alosetron and the 5-HT1P agonist sumatriptan), CCK-1 antagonists (e.g. dexloxiglumide), opioid agonists (e.g. asimadoline), N-methyl-D-aspartate (NMDA) receptor antagonists (e.g dextromethorphan), neurokinin antagonists (e.g. talnetant), capsaicin-like agents and antidepressants are among the agents currently under investigation. It seems unlikely, however, that targeting a single mechanism with an individual drug will result in complete symptom remission in most cases. .